Effect of candesartan on coronary flow reserve in patients with systemic hypertension

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Hypertension is associated with detrimental changes in both conductance and resistance vessels.
• Coronary microvascular function can be assessed by evaluating coronary reserve in the absence of significant coronary artery disease.
• Understanding the impact of antihypertensive medications on coronary microvasculature is crucial for patient management.

Purpose of the Study:

• To non-invasively evaluate the effect of candesartan on coronary microvascular function in patients with hypertension.
• To assess changes in coronary flow reserve (CFR) following treatment with candesartan.

Main Methods:

• Twenty-two hypertensive patients without coronary disease underwent assessment of blood pressure (BP), carotid intima-medial thickness (IMT), left ventricle mass index (LVMI), and coronary flow reserve (CFR) via echocardiography.
• Measurements were taken at baseline and after 3 months of treatment with 16 mg/day of candesartan.
• A control group of twelve hypertensive patients received no treatment changes for comparison.

Main Results:

• Candesartan treatment led to a significant 15% improvement in CFR (P = 0.001) concurrent with blood pressure reduction.
• No significant changes in CFR were observed in the control group (P = 0.23).
• Carotid intima-medial thickness (IMT) did not show significant modification after 3 months of therapy (P = 0.103).

Conclusions:

• Candesartan effectively improves coronary flow reserve in hypertensive individuals.
• The observed improvement in CFR is independent of blood pressure control or regression of left ventricle mass index.
• Hypertensive patients with initially lower CFR demonstrated a more pronounced response to candesartan therapy, detectable non-invasively via echocardiography.